Literature DB >> 21670465

Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome.

Amy P Hsu1, Elizabeth P Sampaio, Javed Khan, Katherine R Calvo, Jacob E Lemieux, Smita Y Patel, David M Frucht, Donald C Vinh, Roger D Auth, Alexandra F Freeman, Kenneth N Olivier, Gulbu Uzel, Christa S Zerbe, Christine Spalding, Stefania Pittaluga, Mark Raffeld, Douglas B Kuhns, Li Ding, Michelle L Paulson, Beatriz E Marciano, Juan C Gea-Banacloche, Jordan S Orange, Jennifer Cuellar-Rodriguez, Dennis D Hickstein, Steven M Holland.   

Abstract

The syndrome of monocytopenia, B-cell and NK-cell lymphopenia, and mycobacterial, fungal, and viral infections is associated with myelodysplasia, cytogenetic abnormalities, pulmonary alveolar proteinosis, and myeloid leukemias. Both autosomal dominant and sporadic cases occur. We identified 12 distinct mutations in GATA2 affecting 20 patients and relatives with this syndrome, including recurrent missense mutations affecting the zinc finger-2 domain (R398W and T354M), suggesting dominant interference of gene function. Four discrete insertion/deletion mutations leading to frame shifts and premature termination implicate haploinsufficiency as a possible mechanism of action as well. These mutations were found in hematopoietic and somatic tissues, and several were identified in families, indicating germline transmission. Thus, GATA2 joins RUNX1 and CEBPA not only as a familial leukemia gene but also as a cause of a complex congenital immunodeficiency that evolves over decades and combines predisposition to infection and myeloid malignancy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21670465      PMCID: PMC3172785          DOI: 10.1182/blood-2011-05-356352

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  17 in total

Review 1.  Nonsense-mediated mRNA decay in health and disease.

Authors:  P A Frischmeyer; H C Dietz
Journal:  Hum Mol Genet       Date:  1999       Impact factor: 6.150

2.  Haploinsufficiency of GATA-2 perturbs adult hematopoietic stem-cell homeostasis.

Authors:  Neil P Rodrigues; Viktor Janzen; Randolf Forkert; David M Dombkowski; Ashleigh S Boyd; Stuart H Orkin; Tariq Enver; Paresh Vyas; David T Scadden
Journal:  Blood       Date:  2005-04-05       Impact factor: 22.113

3.  Successful allogeneic hematopoietic stem cell transplantation for GATA2 deficiency.

Authors:  Jennifer Cuellar-Rodriguez; Juan Gea-Banacloche; Alexandra F Freeman; Amy P Hsu; Christa S Zerbe; Katherine R Calvo; Jennifer Wilder; Roger Kurlander; Kenneth N Olivier; Steven M Holland; Dennis D Hickstein
Journal:  Blood       Date:  2011-08-03       Impact factor: 22.113

4.  Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia.

Authors:  W J Song; M G Sullivan; R D Legare; S Hutchings; X Tan; D Kufrin; J Ratajczak; I C Resende; C Haworth; R Hock; M Loh; C Felix; D C Roy; L Busque; D Kurnit; C Willman; A M Gewirtz; N A Speck; J H Bushweller; F P Li; K Gardiner; M Poncz; J M Maris; D G Gilliland
Journal:  Nat Genet       Date:  1999-10       Impact factor: 38.330

Review 5.  Defects in the interferon-gamma and interleukin-12 pathways.

Authors:  Sergio D Rosenzweig; Steven M Holland
Journal:  Immunol Rev       Date:  2005-02       Impact factor: 12.988

6.  Clinical features of dominant and recessive interferon gamma receptor 1 deficiencies.

Authors:  Susan E Dorman; Capucine Picard; David Lammas; Klaus Heyne; Jaap T van Dissel; Richard Baretto; Sergio D Rosenzweig; Melanie Newport; Michael Levin; Joachim Roesler; Dinakantha Kumararatne; Jean-Laurent Casanova; Steven M Holland
Journal:  Lancet       Date:  2004 Dec 11-17       Impact factor: 79.321

7.  In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis.

Authors:  Joëlle Michaud; Feng Wu; Motomi Osato; Gregory M Cottles; Masatoshi Yanagida; Norio Asou; Katsuya Shigesada; Yoshiaki Ito; Kathleen F Benson; Wendy H Raskind; Colette Rossier; Stylianos E Antonarakis; Sara Israels; Archie McNicol; Harvey Weiss; Marshall Horwitz; Hamish S Scott
Journal:  Blood       Date:  2002-02-15       Impact factor: 22.113

8.  Mutation of CEBPA in familial acute myeloid leukemia.

Authors:  Matthew L Smith; Jamie D Cavenagh; T Andrew Lister; Jude Fitzgibbon
Journal:  N Engl J Med       Date:  2004-12-02       Impact factor: 91.245

9.  Effect of transcription factor GATA-2 on phagocytic activity of alveolar macrophages from Pneumocystis carinii-infected hosts.

Authors:  Mark E Lasbury; Xing Tang; Pamela J Durant; Chao-Hung Lee
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

10.  Gain-of-function mutation of GATA-2 in acute myeloid transformation of chronic myeloid leukemia.

Authors:  Su-Jiang Zhang; Li-Yuan Ma; Qiu-Hua Huang; Guo Li; Bai-Wei Gu; Xiao-Dong Gao; Jing-Yi Shi; Yue-Ying Wang; Li Gao; Xun Cai; Rui-Bao Ren; Jiang Zhu; Zhu Chen; Sai-Juan Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-04       Impact factor: 11.205

View more
  238 in total

Review 1.  GATA2 deficiency.

Authors:  Amy P Hsu; Lisa J McReynolds; Steven M Holland
Journal:  Curr Opin Allergy Clin Immunol       Date:  2015-02

2.  Loss-of-function germline GATA2 mutations in patients with MDS/AML or MonoMAC syndrome and primary lymphedema reveal a key role for GATA2 in the lymphatic vasculature.

Authors:  Jan Kazenwadel; Genevieve A Secker; Yajuan J Liu; Jill A Rosenfeld; Robert S Wildin; Jennifer Cuellar-Rodriguez; Amy P Hsu; Sarah Dyack; Conrad V Fernandez; Chan-Eng Chong; Milena Babic; Peter G Bardy; Akiko Shimamura; Michael Y Zhang; Tom Walsh; Steven M Holland; Dennis D Hickstein; Marshall S Horwitz; Christopher N Hahn; Hamish S Scott; Natasha L Harvey
Journal:  Blood       Date:  2011-12-06       Impact factor: 22.113

3.  MonoMAC versus idiopathic CD4+ lymphocytopenia. Comment to Haematologica. 2011;96(8):1221-5.

Authors:  Vicki H Chu; Jonathan L Curry; M Tarek Elghetany; Choladda V Curry
Journal:  Haematologica       Date:  2012-04       Impact factor: 9.941

4.  GATA2 mutations lead to MDS and AML.

Authors:  R Katherine Hyde; P Paul Liu
Journal:  Nat Genet       Date:  2011-09-28       Impact factor: 38.330

Review 5.  Anemia of Central Origin.

Authors:  Kazusa Ishii; Neal S Young
Journal:  Semin Hematol       Date:  2015-07-09       Impact factor: 3.851

6.  Sequencing of RNA in single cells reveals a distinct transcriptome signature of hematopoiesis in GATA2 deficiency.

Authors:  Zhijie Wu; Shouguo Gao; Carrie Diamond; Sachiko Kajigaya; Jinguo Chen; Rongye Shi; Cindy Palmer; Amy P Hsu; Katherine R Calvo; Dennis D Hickstein; Steven M Holland; Neal S Young
Journal:  Blood Adv       Date:  2020-06-23

Review 7.  Natural killer cell deficiency.

Authors:  Jordan S Orange
Journal:  J Allergy Clin Immunol       Date:  2013-09       Impact factor: 10.793

Review 8.  Warts and all: human papillomavirus in primary immunodeficiencies.

Authors:  Jennifer W Leiding; Steven M Holland
Journal:  J Allergy Clin Immunol       Date:  2012-10-01       Impact factor: 10.793

Review 9.  Learning from other diseases: protection and pathology in chronic fungal infections.

Authors:  Teresa Zelante; Giuseppe Pieraccini; Lucia Scaringi; Franco Aversa; Luigina Romani
Journal:  Semin Immunopathol       Date:  2015-09-17       Impact factor: 9.623

10.  High frequency of GATA2 mutations in patients with mild chronic neutropenia evolving to MonoMac syndrome, myelodysplasia, and acute myeloid leukemia.

Authors:  Marlène Pasquet; Christine Bellanné-Chantelot; Suzanne Tavitian; Naïs Prade; Blandine Beaupain; Olivier Larochelle; Arnaud Petit; Pierre Rohrlich; Christophe Ferrand; Eric Van Den Neste; Hélène A Poirel; Thierry Lamy; Marie Ouachée-Chardin; Véronique Mansat-De Mas; Jill Corre; Christian Récher; Geneviève Plat; Françoise Bachelerie; Jean Donadieu; Eric Delabesse
Journal:  Blood       Date:  2012-12-06       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.